CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research conducted by CNSP founder Dr. Waldemar Priebe that studies the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, Climaco discussed CNS Pharmaceuticals’ lead drug candidate, Berubicin. The drug is being proposed as a treatment for GBM. A Phase I clinical trial evaluating the drug has been completed, and CNS has applied to begin a Phase II clinical trial. Climaco noted the slow progress in treatments for glioblastoma and observed that Berubicin has potential to significantly impact the prognosis for GBM patients worldwide. “Berubicin looks and acts and kills cancer cells just like every other anthracycline, but the secret sauce is that it gets into the brain,” Climaco said. “What Dr. Priebe did was address a very defined and, in the grand scheme, a small innovation, but it’s an absolutely critical innovation for the application of this type of drug to this type of cancer. We are laser-focused on designing the best possible study for this drug in the best environment with the best patients. With our partner in Europe, we’re expecting to test almost 300 patients over the next couple of years.”
To hear the full podcast, visit https://ibn.fm/6JvEN
To view the full press release, visit https://ibn.fm/B1hnM
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork